VTE Prophylaxis in Critical Care — Part 1: Epidemiology, Risk Factors & Risk Assessment

Epidemiology of VTE in Critical Illness

Incidence

Venous thromboembolism — encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE) — is one of the most common preventable complications of hospitalization. In the intensive care unit, the convergence of multiple risk factors creates a uniquely high-risk environment.^{1 2}

Note: Incidence figures represent ranges derived from studies using screening compression ultrasonography or venography. Actual rates depend on the timing and modality of screening, prophylaxis regimen used, and patient case-mix.^{1 2 3}

Proximal vs Distal DVT

The clinical significance of DVT location in the ICU is important for risk stratification:

• Proximal DVT (popliteal, femoral, iliac veins): Carries a 40–50% risk of PE if untreated; requires therapeutic anticoagulation
• Distal DVT (calf veins — peroneal, posterior tibial, anterior tibial): Lower PE risk (~5%); may be monitored with serial imaging or treated, depending on clinical context
• Catheter-related upper extremity DVT: Occurs in 5–18% of patients with central venous catheters (internal jugular, subclavian, femoral); may be asymptomatic; PE risk ~6%⁴

Fatal PE in the ICU

Fatal PE accounts for approximately 10% of all in-hospital deaths. Autopsy studies demonstrate that PE is unsuspected clinically in up to 70–80% of fatal cases. In the ICU specifically, PE is the third most common cardiovascular cause of death after myocardial infarction and stroke.⁵

Pathophysiology: Virchow’s Triad in Critical Illness

The three elements of Virchow’s triad — venous stasis, endothelial injury, and hypercoagulability — are virtually universally present in critically ill patients.²

Venous Stasis

• Immobility: Bed rest, sedation, neuromuscular blockade, and physical restraints eliminate the calf muscle pump
• Mechanical ventilation: Positive-pressure ventilation reduces venous return and increases lower extremity venous pressure
• Vasopressor use: Peripheral vasoconstriction may impair venous flow

Endothelial Injury

• Central venous catheterization: Direct vessel wall injury at insertion site; catheter-associated endothelial activation
• Surgical trauma: Tissue injury with local endothelial disruption
• Sepsis-related endotheliopathy: Systemic endothelial activation with glycocalyx shedding and procoagulant surface expression

Hypercoagulability

• Acute phase response: Elevated fibrinogen, factor VIII, von Willebrand factor, and C-reactive protein
• Sepsis-induced coagulopathy: Tissue factor expression, impaired protein C/S pathway, reduced antithrombin levels, complement activation
• Post-surgical state: Tissue factor release, platelet activation
• Malignancy-associated: Tumor-derived tissue factor, cancer procoagulant, mucin-mediated platelet aggregation
• Medications: Vasopressors, estrogen-containing therapies, tranexamic acid

VTE Risk Factors in the ICU

Patient-Related (Intrinsic) Risk Factors

ICU-Specific (Acquired) Risk Factors

Risk Assessment Models

The Padua Prediction Score (Medical Patients)

The Padua Prediction Score is the most widely validated risk assessment model for VTE in acutely ill medical patients. It was developed to identify patients at high risk for VTE who would benefit from pharmacologic prophylaxis.⁶

Scoring Table

Interpretation

Validation: In the original validation cohort (n = 1,180), patients with a Padua score ≥4 who did not receive prophylaxis had a VTE incidence of 11.0% versus 2.2% in those who received LMWH or UFH.⁶

ICU Application: Nearly all ICU patients score ≥4 on the Padua scale due to the near-universal presence of reduced mobility (3 points) plus at least one additional risk factor. This effectively makes almost every ICU admission a high-risk scenario requiring prophylaxis unless contraindicated.

The Caprini Score (Surgical Patients)

The Caprini Risk Assessment Model is the most extensively validated tool for VTE risk stratification in surgical patients. It stratifies patients into risk categories to guide the intensity and duration of thromboprophylaxis.^{7 8}

Scoring Table

1-Point Risk Factors:

2-Point Risk Factors:

3-Point Risk Factors:

5-Point Risk Factors:

Interpretation

Key Points:

• Score is additive — each patient may have multiple risk factors contributing to the total
• The Caprini score is validated in general, vascular, urologic, gynecologic, plastic, and otolaryngologic surgery⁸
• Nearly all ICU surgical patients score ≥5, placing them in the high-risk category
• Patients with Caprini score ≥9 should receive combined pharmacologic and mechanical prophylaxis

The IMPROVE VTE Risk Score (Medical Patients)

The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score was developed in a multinational cohort of acutely ill medical patients to predict VTE risk and guide prophylaxis decisions.⁹

VTE Risk Score

VTE Risk Interpretation

IMPROVE Bleeding Risk Score

The IMPROVE investigators also developed a companion bleeding risk score to help balance VTE prevention against hemorrhagic risk:¹⁰

Bleeding Risk Interpretation

ICU-Specific Risk Considerations

Standard risk assessment models (Padua, Caprini, IMPROVE) were not developed specifically for ICU populations and have important limitations when applied to critically ill patients:^{1 11}

1. Ceiling effect: Nearly all ICU patients score in the high-risk category on the Padua scale (≥4 points) and Caprini score (≥5), making these tools less useful for further risk stratification within the ICU

2. Dynamic risk: ICU patients’ VTE risk changes rapidly with evolving clinical status — new surgery, new central lines, onset of sepsis, initiation/discontinuation of vasopressors, or transition to mobilization

3. Bleeding risk assessment: Validated tools for balancing VTE and bleeding risk in ICU populations are lacking. The IMPROVE bleeding score includes ICU admission as a risk factor but does not account for many ICU-specific bleeding risks (coagulopathy, thrombocytopenia, recent invasive procedures, stress ulceration)

4. Recommended approach in the ICU:

   • Assume all ICU patients are at high risk for VTE unless proven otherwise
   • Perform daily reassessment of both VTE risk AND bleeding risk
   • Initiate pharmacologic prophylaxis as soon as the bleeding risk is acceptably low
   • Use mechanical prophylaxis when pharmacologic prophylaxis is contraindicated
   • Document risk assessment and prophylaxis decisions daily

Practical ICU Decision Framework

Key Principles

1. Universal prophylaxis: All critically ill patients should receive VTE prophylaxis unless there is a specific contraindication
2. Pharmacologic preferred: When not contraindicated by active bleeding or high bleeding risk, pharmacologic prophylaxis is superior to mechanical prophylaxis alone
3. LMWH over UFH: In most critically ill patients, LMWH is preferred over UFH based on evidence of similar efficacy with a potentially lower incidence of heparin-induced thrombocytopenia⁵
4. Standard dose is default: For the general ICU population without COVID-19, standard-dose prophylaxis is recommended over intermediate or therapeutic-dose prophylaxis¹²
5. Daily reassessment: Both VTE risk and bleeding risk should be reassessed at least daily, with prophylaxis strategy adjusted accordingly
6. Prompt initiation: Pharmacologic prophylaxis should be started as soon as the bleeding risk is judged acceptable — delays in initiation are a major contributor to preventable VTE events
7. Documentation: Risk assessment, prophylaxis decisions, and any contraindications should be documented in the medical record daily